Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of HSK44459 tablets, which are aimed at treating inflammatory bowel disease, including ulcerative colitis and Crohn's disease [1] Group 1 - HSK44459 tablets are a new small molecule drug developed by the company specifically for inflammatory bowel disease [1] - Preclinical studies indicate that HSK44459 has a clear target, definite efficacy, and good safety profile, suggesting a broad clinical application potential [1] - The company will disclose information in a timely manner based on the progress of the project [1]

Core Insights - The company and its subsidiaries have received approval for six drug clinical trials, which will commence shortly [1] Drug Details - SHR-4375 injection: A self-developed therapeutic biological product targeting tumor cell surface antigens, intended for advanced malignant solid tumors, entering phase Ib/II clinical research. Cumulative R&D investment is 44.88 million [6] - Adebali monoclonal antibody injection: An anti-PD-L1 monoclonal antibody that was approved for marketing in February 2023, now undergoing clinical trials for a new indication. Cumulative R&D investment is 969.8 million [6] - Bevacizumab injection: An anti-VEGF monoclonal antibody approved for marketing in June 2021, now also undergoing clinical trials for a new indication. Cumulative R&D investment is 364.73 million [6] - SHR-8068 injection: An introduced anti-CTLA-4 monoclonal antibody with a cumulative R&D investment of 262.18 million [6] - HRS-4642 injection: A self-developed KRAS G12D inhibitor in liposome formulation, with no similar drugs approved domestically or internationally. Cumulative R&D investment is 190.65 million [6] - SHR-9839 injection: A self-developed dual-target humanized antibody in subcutaneous injection form, with a cumulative R&D investment of 72.31 million [6]

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of HRS-6257, a drug intended for postoperative analgesia, marking a significant step in its development pipeline [1] Group 1: Company Developments - Heng Rui Medicine's subsidiary, Shanghai Heng Rui Medicine Co., Ltd., has been granted a Clinical Trial Approval Notice for HRS-6257 [1] - The drug is aimed at treating acute and chronic pain, with no similar target drugs approved in the domestic market [1] - The total research and development investment for the project has reached approximately 15.58 million yuan [1] Group 2: Regulatory and Market Context - The approval allows the company to conduct clinical trials, which must be completed and reviewed by the National Medical Products Administration before the drug can be manufactured and marketed [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of HRS-6257 tablets, aimed at treating acute and chronic pain, with no similar drugs currently approved in the domestic market [1] Group 1 - The subsidiary Shanghai Hengrui Medicine Co., Ltd. has been authorized to conduct clinical trials for HRS-6257 tablets [1] - HRS-6257 is intended for the treatment of acute and chronic pain [1] - There are currently no approved drugs targeting the same mechanism in the domestic market [1]

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of HRS-6257 tablets, aimed at treating acute and chronic pain, with no similar drugs approved in the domestic market [1] Company Summary - Heng Rui Medicine's subsidiary, Shanghai Heng Rui Medicine Co., Ltd., has been granted a Clinical Trial Approval Notice for HRS-6257 tablets [1] - The total research and development investment for the HRS-6257 project has reached approximately 15.58 million yuan [1] Industry Summary - Currently, there are no approved drugs targeting the same mechanism as HRS-6257 in the domestic market [1]

Core Viewpoint - Biotech company Abivax (ABVX.US) saw a pre-market increase of 3.58%, reaching $147.4, following an upgrade from Guggenheim, which raised the target price from $150 to $175 and maintained a "Buy" rating based on optimistic expectations for its core drug obefazimod's upcoming data release [1] Group 1 - Abivax's stock price increased by 3.58% to $147.4 in pre-market trading [1] - Guggenheim raised Abivax's target price from $150 to $175 [1] - Analyst Yatin Suneja expressed optimism regarding the data readout for obefazimod at week 44 [1]

Core Viewpoint - Biotech company Abivax (ABVX.US) saw a pre-market increase of 3.58%, reaching $147.4, following an upgrade from Guggenheim, which raised the target price from $150 to $175 and maintained a "Buy" rating based on optimistic expectations for its core drug obefazimod's upcoming data release [1]. Stock Performance - The closing price on December 26 was $142.31, reflecting a decrease of 2.06% [1] - The pre-market price on December 29 was $147.4, an increase of $5.09 [1] - The stock reached a high of $144.89 and a low of $139.42 during the trading session [1] - The average price was $141.665, with a trading volume of 665,100 shares [1] Financial Metrics - The total market capitalization of Abivax is approximately $11.09 billion [1] - The total share count is 77.93 million, with a circulating value of $5.98 billion [1] - The price-to-earnings ratio is currently at a loss, and the price-to-book ratio is 18.431 [1] Historical Performance - The stock has a 52-week high of $148.83 and a low of $4.77 [1] - The historical highest price recorded is $148.83, while the lowest is $4.77 [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the clinical trial of Hydroxocobalamin injection, indicating progress in its drug development pipeline [1] Group 1: Regulatory Approval - The company announced on December 29 that it received the clinical trial approval notice for Hydroxocobalamin injection from the National Medical Products Administration [1] - The acceptance notice for the drug was received on October 22, 2025, and the clinical trial approval was granted on December 25, 2025 [1] Group 2: Financial Investment - As of the date of the announcement, the company has invested a total of RMB 13.0581 million (approximately 1.3 million) in the research and development of this drug [1] Group 3: Indication - Hydroxocobalamin injection is indicated for the treatment of metabolic disorders in children with methylmalonic acidemia, with or without homocystinuria [1]

Core Viewpoint - The company is committed to dual-track research in traditional Chinese medicine (TCM) and chemical drugs, aiming to enhance product quality and market competitiveness through innovation [1] Group 1: Traditional Chinese Medicine (TCM) Development - The company is focusing on the inheritance and development of existing TCM products, conducting clinical and real-world studies for secondary development of key TCM products [1] - The goal is to grow distinctive TCM products, such as cough tablets, skin disease blood detox pills, and blood sugar-lowering pills, into major TCM varieties to enhance brand influence [1] - The company is actively seizing opportunities in the TCM industry by strengthening collaborations with relevant research institutions to develop innovative TCM drugs [1] Group 2: Chemical Drug Research - The company is conducting integrated innovation research on "active pharmaceutical ingredients + formulations," focusing on cutting-edge research for drugs treating major diseases [1] - The approach involves a synergistic model of developing both formulations and active pharmaceutical ingredients to improve overall research efficiency [1]

Core Insights - Biohaven's experimental depression drug failed to meet the primary endpoint in a mid-stage trial, indicating ongoing challenges for the company in its drug development efforts [1] Company Summary - The recent trial setback adds to a series of difficulties faced by Biohaven this year, including other trial and regulatory issues [1]